you are here: HomeNewsBusiness

Most mutual funds may fail to benefit from RBI’s liquidity window - here is why: Report

To avail the Rs 50,000 crore liquidity window till May 11, funds will be allowed to borrow against investment grade credit risk schemes

April 28, 2020 / 09:27 AM IST

Most mutual funds may fail to take advantage of the liquidity window provided by the Reserve Bank of India (RBI) as many credit risk schemes are low on top-rated papers - offloaded due to redemption pressure from the coronavirus pandemic, The Economic Times reported.

To avail the Rs 50,000 crore liquidity window till May 11, set up for the mutual fund (MF) sector by the RBI, funds will be allowed to borrow against investment grade credit risk schemes.

Industry officials, however, are concerned this may not be enough as banks may be unwilling to accept the majority of the low-rated securities as collateral, especially since the period of holding is short – only till May 11, they told the paper.

Follow our LIVE Updates on the coronavirus pandemic here

RBI’s liquidity window came after Franklin Templeton had closed six funds citing financial crunch due to the COVID-19 situation.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

“I don’t see banks taking lower-rated corporate debt as collateral, which have been lacking in liquidity. If we see heavy redemption in schemes which carry large exposure to lower-rated corporate debt, liquidity will remain a problem,” Arvind Chari, head — fixed income, Quantum Advisors, told ET.

An advantage, however, is that MFs can raise money by pledging their papers, rather than selling them. MF credit risk schemes held by banks are also more attractive. “AMCs which are backed by banks will not have much of a problem unless the quality of paper is bad. The parent will buy it through the TLTRO route,” said the chief investment officer of a wealth management firm.

Follow our full COVID-19 coverage here
Moneycontrol News
first published: Apr 28, 2020 09:27 am

stay updated

Get Daily News on your Browser
Sections